PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29187872-0 2017 Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients. Sunitinib 41-50 annexin A1 Homo sapiens 8-13 29187872-4 2017 Our aim with the current study was to assess annexin A1 (ANXA1), which stimulates angiogenesis, as a predictive marker for sunitinib therapy in mRCC patients. Sunitinib 123-132 annexin A1 Homo sapiens 45-55 29187872-4 2017 Our aim with the current study was to assess annexin A1 (ANXA1), which stimulates angiogenesis, as a predictive marker for sunitinib therapy in mRCC patients. Sunitinib 123-132 annexin A1 Homo sapiens 57-62 29187872-13 2017 Conclusions: Our results indicate that cytoplasmic expression of ANXA1 is a negative predictive marker for sunitinib therapy in mRCC patients. Sunitinib 107-116 annexin A1 Homo sapiens 65-70